| Norton Healthcare

A Phase 3 randomized double-blind placebo-controlled stud) toevaluate the efficacy and safety of ralinepag when added topulmonary arterial hypertension (PAH) standard of care orPAI-l-specific background oral therapy in subjects with WorldHealth Organizati

Drug Study

Principal Investigator: John McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: UNITED THERAPEUTICS CORPORATION

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.